Turn Therapeutics Inc. (TTRX)
NASDAQ: TTRX · Real-Time Price · USD
8.89
+0.34 (3.98%)
Nov 18, 2026, 4:00 PM EST - Market closed
Company Description
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye.
The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025.
Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California.
Turn Therapeutics Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Bradley Burnam |
Contact Details
Address: 250 N Westlake Blvd, STE 210 Westlake Village, California 91362 United States | |
| Phone | 818 546 4011 |
| Website | turntherapeutics.com |
Stock Details
| Ticker Symbol | TTRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 2023016 |
| CUSIP Number | 90021W105 |
| ISIN Number | US90021W1053 |
| Employer ID | 32-0456090 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bradley E. Burnam | Founder, Chief Executive Officer and Director |
| Zuraiz Chaudhary | Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer |
| Dr. Neilesh Shailesh Ghodadra M.D. | Chief Medical Officer and Director |
| Dr. Robert R. Redfield M.D. | Chief Scientific Officer |
| Mohammed Zubair | Controller |
| Dr. Stephen M. Hahn FASTRO, M.D. | Executive Clinical and Regulatory Lead |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 16, 2026 | EFFECT | Notice of Effectiveness |
| Nov 16, 2026 | EFFECT | Notice of Effectiveness |
| Nov 16, 2026 | 424B5 | Filing |
| Nov 16, 2026 | 424B3 | Prospectus |
| Nov 10, 2026 | 8-K | Current Report |
| Nov 9, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 9, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 9, 2026 | 10-Q | Quarterly Report |
| Nov 9, 2026 | 8-K | Current Report |
| Oct 19, 2026 | ARS | Filing |
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides